Last reviewed · How we verify
REMD-477
At a glance
| Generic name | REMD-477 |
|---|---|
| Also known as | Volagidemab |
| Sponsor | REMD Biotherapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery (PHASE1)
- Effects of GRA in Patients With Type 1 (PHASE2)
- Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM (EARLY_PHASE1)
- Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus (PHASE2)
- Combination GRA and SGLT-2i Treatment in Type 1 Diabetes (PHASE1, PHASE2)
- Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) (PHASE1)
- Metabolic Pathways of GRA in Patients With Type 1 Diabetes (PHASE1, PHASE2)
- A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REMD-477 CI brief — competitive landscape report
- REMD-477 updates RSS · CI watch RSS
- REMD Biotherapeutics, Inc. portfolio CI